Fast-track screening to determine eligibility for anti-amyloid treatment using digital cognitive tests and blood biomarkers.

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

Up to 500 patients referred to the MoCA Clinic with cognitive complaints will complete digital cognitive screening (MoCA Cognition/XpressO) and provide blood samples for biomarker assays (including PrecivityAD2 and MTBR). Demographics, health questionnaires, cognitive scores, biomarker levels, and neurologist determinations of DMT eligibility will be collected. Data will be used to build an algorithm to triage patients into a fast‑track diagnostic pathway and to estimate follow‑up testing needs (MRI, PET, CSF). Exploratory analyses will validate self‑administered tools, estimate health‑economic impacts, and identify predictors of cognitive decline.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Must be referred to the MoCA Clinic; including both new patients and existing patients who have been seen \>1 year ago
* Present with cognitive impairment or cognitive complaints.
* Must have the ability to understand the purpose and risk of the Study and provide informed consent.
* Must have an identified study partner (informant/care partner), who has frequent and sufficient contact with the participant to be able to provide accurate information about the participant's cognitive and functional abilities. The study partner must be available by phone to provide information to the study staff about the participant and agrees to attend one in-person visit at the MoCA Clinic which requires partner input. The study partner should be available for the duration of the study.

Exclusion Criteria:

* An established diagnosis (other than AD), that is a cause for a candidate's cognitive impairment (e.g. substance abuse, cerebrovascular conditions, Lewy body dementia, fronto-temporal dementia, recent head trauma).
* Blood donation (1 unit) within 1 month prior to Study screening.
* Inability to comply with requirements to complete essential components of the Study (e.g. visual impairment, severe kidney disease or ongoing kidney treatment)
* Patients already enrolled in any clinical trial for AD at time of Study screening
* Other unspecified reasons that, in the opinion of the Principal Investigator, or MoCA Clinic and Institute, make the candidate unsuitable for enrolment.

Where it's running

• MoCA Clinic and Institute
  Greenfield Park, Quebec, Canada Recruiting

Study contacts

• Principal investigator: Ziad Nasreddine, MD — MoCA Clinic
• Study coordinator: Johanna Gruber, MSc
• Email: johanna.gruber@mocacognition.com
• Phone: 5147585033

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Gut methane and Parkinson's: measuring if a probiotic helps people with Parkinson's, REM sleep behavior disorder, or cognitive concerns

  This study tests whether a probiotic containing Limosilactobacillus reuteri can help people with Parkinson's disease, those at high risk for PD, and related cognitive issues by potentially improving gut methane levels and overall symptoms.

  Recruiting University of Cambridge · Cambridge, CB2 · NCT07786116

• Blood tests using plasma biomarkers to diagnose and track Alzheimer’s disease

  A large, year-long study in Milan is testing whether blood markers can help diagnose Alzheimer’s and predict how it will progress in people with memory concerns.

  Recruiting IRCCS San Raffaele · Milan, Milano · NCT07717567

• Music for Pain and Dementia: Group Drumming for people with early dementia and their caregivers

  This study tests whether group drumming can reduce pain and change brain activity in people with mild dementia or mild cognitive impairment and in their caregivers.

  Recruiting Yale University · New Haven, Connecticut · NCT07602283

• Ultralow-dose amyloid PET with 18F‑Florbetapir or 18F‑Flutemetamol

  This trial will try using a very small amount of an amyloid PET tracer with a high-sensitivity PET scanner to see if clear brain images can be made for people with Alzheimer’s, mild cognitive impairment, other dementias, and healthy volunteers.

  Recruiting Phase 2 Nuclear Imaging Institute · Englewood, New Jersey · NCT07012993

• Korean Joint Registry for Alzheimer's Treatment and Diagnostics

  This study is testing new Alzheimer's treatments, like lecanemab and donanemab, to see how well they work and are safe for people with Alzheimer's in South Korea.

  Recruiting at 2 sites Ewha Womans University Mokdong Hospital · Incheon and 2 other locations · NCT06889818

• Using brain stimulation and digital training to improve cognitive function in older adults

  This study is testing whether a combination of brain stimulation and digital training can help improve thinking skills in older adults with Mild Cognitive Impairment and Alzheimer's Disease.

  Recruiting Universidade Federal do Rio de Janeiro · Rio de Janeiro, Rio de Janeiro · NCT06733714

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.